Lonza 2024

To date, more than 10 antibody-drug conjugates (ADCs) have been approved by the U.S. Food and Drug Administration (FDA) and contribute to the medical community.

Interestingly, all of them are manufactured using chemical conjugation techniques [1]. This demonstrates that chemical conjugation is the primary approach to ADC manufacturing. Compared to other conjugation techniques (e.g., genetic engineering or enzymatic), chemical conjugation has the advantage of a relatively simple chemistry, manufacturing, and control (CMC) for ADC, prompting pharmaceutical companies to choose this technique for ADC projects [2].

To better understand this advantage, this article provides an overview of established full chemical conjugation methods that have already been applied in the scale-up phase for ADC production.

Read Full Article

Advertisement #3 

Corresponding Author: Yutaka Matsuda, Ph.D. E-mail: Yutaka Matsuda, Ph.D.

Key terms: ADC, bioconjugation, differential antigen expression, simultaneous delivery of drugs
Published In: ADC Review| Journal of Antibody-drug Conjugates

DOI: https://doi.org/10.14229/jadc.2023.01.05.002.

How to cite:
Matsuda Y.1 Recent advances in antibody-drug conjugates produced using chemical conjugation technology – J. ADC. January 5, 2023. DOI: 10.14229/jadc.2023.01.05.002.

1Ajinomoto Bio-Pharma Services, San Diego, CA 92121

Last Editorial Review: December 26, 2022

Creative Commons License

Article History:

  • Original Manuscript Received December 15, 2022
  • Review results received December 20, 2022
  • Manuscript accepted for publication December 27, 2023

Featured image: Bioconjugation. Photo courtesy: © 2016 – 2023 – Ajinomoto Bio-Pharma Services, San Diego. Used with permission.

Advertisement #4